GSK plc (GSK)

Quick facts

Marketed products

• Tivicay · Immunology · revenue 5200
  Tivicay blocks the integrase enzyme, preventing HIV from integrating its genetic material into the host cell's DNA.
• Shingrix · Immunology · revenue 4300
• Vocabria · Immunology · revenue 2100
  Vocabria works by blocking the integrase enzyme, which is necessary for the virus to replicate.
• Nucala · Respiratory · revenue 1600
  Nucala works by binding to interleukin-5, a protein that stimulates the production of eosinophils.
• Jemperli · Oncology · revenue 800
  Dostarlimab-gxly binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.
• Zejula · Oncology · revenue 600
  Zejula works by blocking the action of an enzyme called PARP, which helps repair damaged DNA in cancer cells.
• Blenrep · Oncology · revenue 300
  Belantamab mafodotin binds to BCMA on multiple myeloma cells, is internalized, and releases a cytotoxic agent that disrupts microtubules, causing cell death.
• Ziagen · Immunology
  Abacavir works by mimicking a building block of DNA, tricking the virus into incorporating it into its genetic material and preventing replication.
• ADOAIR250 · Other
• Albugon · Metabolic
• Agenerase · Immunology
• BOOSTRIX · Immunology
• Nuceiva · Neuroscience
  Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions.
• Wellbutrin · Metabolic
  Norepinephrine-dopamine reuptake inhibitor (NDRI) that treats depression and aids smoking cessation without serotonergic side effects.
• Ancef In Sodium Chloride 0.9% In Plastic Container · Metabolic
• Ancef In Sodium Chloride 0.9% In Plastic Container · Metabolic
  Cefazolin is an antibacterial drug that inhibits bacterial cell wall synthesis.
• Zinacef · Cardiovascular
  Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Ceftin · Infectious Disease
  Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death.
• Cetanol · Respiratory
• Methocillin S · Metabolic
• L-Dipalmitoyl Lecithin · Metabolic
• Marezine · Immunology
• Jesduvroq · Hematology
  Jesduvroq works by activating hypoxia-inducible factor prolyl hydroxylase inhibitors, which increases the production of erythropoietin, a hormone that stimulates red blood cell production.
• Rescriptor · Immunology
• Exdensur · Respiratory
  Exdensur works by binding to histamine, preventing it from interacting with its receptors and reducing inflammation and airway constriction.
• EXDENSUR · Other
  Depemokimab-ulaa binds to IL-5, blocking its interaction with the IL-5 receptor and reducing eosinophil activity.
• Hispril · Infectious Disease
• JEMPERLI · Oncology
  Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response.
• Avodart · Metabolic
  Dual 5-alpha-reductase inhibitor (types I and II) that more completely suppresses DHT than finasteride for BPH treatment.
• Flonase · Oncology
• Lexiva · Immunology
  Lexiva works by blocking the protease enzyme, which is necessary for HIV to replicate.
• Rukobia · Immunology
  Rukobia works by blocking the potassium voltage-gated channel subfamily H member 2, which is involved in the replication of the human immunodeficiency virus 1.
• FPNS · Other
• Blujepa · Infectious Disease
  Blujepa works by inhibiting bacterial DNA polymerase, preventing the replication of bacterial DNA and ultimately leading to bacterial cell death.
• Halfan · Rare Disease
• HAVRIX · Immunology
• Brexafemme · Infectious Disease
• Brexafemme · Infectious Disease
• IPOL · Other
• Isopropamid · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• GSK plc portfolio CI brief
• GSK plc pipeline updates RSS